Mr. Hugh Rogers reports

BIONXT SOLUTIONS ANNOUNCES REVOCATION OF MANAGEMENT CEASE TRADE ORDER

Effective immediately, the British Columbia Securities Commission has revoked the temporary management cease trade order (MCTO) Bionxt Solutions Inc. had previously granted to the company on May 1, 2025, under National Policy 12-203 -- Management Cease Trade Orders, as the company successfully completed the filing of its annual audited financial statements, management's discussion and analysis, and related certifications for the year ended Dec. 31, 2024 (collectively, the annual filings), on June 26, 2025.

The revocation of the MCTO means members of management are no longer prevented from trading the company's securities. All of the annual filings are available under the company's profile on SEDAR+.

About Bionxt Solutions Inc.

Bionxt Solutions is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems and active pharmaceutical ingredient development. The company's proprietary platforms -- sublingual (thin film), transdermal (skin patch) and oral (enteric-coated tablets) -- target key therapeutic areas, including autoimmune diseases, neurological disorders and longevity.

With research and development operations in North America and Europe, Bionxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. Bionxt is committed to improving health care by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.

We seek Safe Harbor.